Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 19/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 19/20 | 0.62 |
| ▸ | PDE4C | Q08493 | 19/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 19/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4699341 | 0.84 | PDE4D (0.63) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4753045 | 0.83 | PDE4A (0.67) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4704462 | 0.77 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4699266 | 0.77 | PDE4D (0.69) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6586085 | 0.77 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4699329 | 0.76 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6688261 | 0.76 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6589078 | 0.76 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6587900 | 0.76 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6589991 | 0.76 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581229-B1 | PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON SPA (IT) | 2008-03-12 | — | — | EP | disclosed |
| US-20060166996-A1 | Phthalazine derivatives as phosphodiesterase 4 inhibitors | ZAMBON GROUP S.P.A. (IT) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166996-A1 | Phthalazine derivatives as phosphodiesterase 4 inhibitors | PDE4A, PDE5A, PDE2A | PDE4A 1/4885PDE4B 6/4885PDE4C 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.